Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Delivers Lead Compound To BioChem Pharma

Premium

SAN DIEGO--Privately held Structural Bioinformatics here announced that BioChem Pharma, a Canadian biopharmaceutical company, has accepted a lead compound for the treatment of a human viral infectious disease, triggering a milestone payment in the company's collaboration with BioChem Pharma.

Structural Bioinformatics began collaborating with BioChem in August 1997 to find leads for certain viral and cancer targets.

The new lead compound will now be further developed by BioChem. Structural Bioinformatics will receive future fees upon the fulfillment of additional milestones, including the successful completion of clinical trials.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.